

DAFTAR PUSTAKA

- Barnum, K. J., & O'Connell, M. J. (2014). Cell cycle regulation by checkpoints. *Methods in Molecular Biology*, 1170, 29–40. https://doi.org/10.1007/978-1-4939-888-2_2
- Besson, A., Dowdy, S. F., & Roberts, J. M. (2008). CDK Inhibitors: Cell Cycle Regulators and Beyond. *Developmental Cell*, 14(2), 159–169. <https://doi.org/10.1016/j.devcel.2008.01.013>
- Bouri, S., Simon, P., D'Haene, N., Catteau, X., & Noël, J. C. (2020). P53 and PIK3CA Mutations in KRAS/HER2 Negative Ovarian Intestinal-Type Mucinous Carcinoma Associated with Mature Teratoma. *Case Reports in Obstetrics and Gynecology*, 2020, 8–11. <https://doi.org/10.1155/2020/8863610>
- Callahan, M. J., Crum, C. P., Medeiros, F., Kindelberger, D. W., Elvin, J. A., Garber, J. E., Feltmate, C. M., Berkowitz, R. S., & Muto, M. G. (2007). Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. *Journal of Clinical Oncology*, 25(25), 3985–3990. <https://doi.org/10.1200/JCO.2007.12.2622>
- Critchley, H. O. D., Babayev, E., Bulun, S. E., Clark, S., Garcia-Grau, I., Gregersen, P. K., Kilcoyne, A., Kim, J. Y. J., Lavender, M., Marsh, E. E., Matteson, K. A., Maybin, J. A., Metz, C. N., Moreno, I., Silk, K., Sommer, M., Simon, C., Tariyal, R., Taylor, H. S., ... Griffith, L. G. (2020). Menstruation: science and society. *American Journal of Obstetrics and Gynecology*, 223(5), 624–664. <https://doi.org/10.1016/j.ajog.2020.06.004>
- Erickson, B. K., Conner, M. G., & Landen, C. N. (2013). The role of the fallopian tube in the origin of ovarian cancer. *American Journal of Obstetrics and Gynecology*, 209(5), 409–414. <https://doi.org/10.1016/j.ajog.2013.04.019>
- GLOBOCAN. (2020). Ovarian Cancer Incidence and Mortality. *International Agency for Research on Cancer (IARC) GLOBOCAN*, 5–6. <https://gco.iarc.fr/today/data/factsheets/cancers/25-Ovary-fact-sheet.pdf>
- Granström, C., Sundquist, J., & Hemminki, K. (2008). Population attributable fractions for ovarian cancer in Swedish women by morphological type. *British Journal of Cancer*, 98(1), 199–205. <https://doi.org/10.1038/sj.bjc.6604135>
- Hosea, R., & Hillary, Sharon, Wu, S. (2023). *Targeting Transcription Factor YY1 for Cancer Treatment : Current Strategies and Future Directions*.
- Karst, A. M., & Drapkin, R. (2010). Ovarian Cancer Pathogenesis: A Model in Evolution. *Journal of Oncology*, 2010, 1–13. <https://doi.org/10.1155/2010/932371>
- Kindelberger, D. W., Lee, Y., Miron, A., Hirsch, M. S., Feltmate, C., Medeiros, F., Callahan, M. J., Garner, E. O., Gordon, R. W., Birch, C., Berkowitz, R. S., Muto, M. G., & Crum, C. P. (2007). *Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma : Evidence for a Causal Relationship*. 31(2), 161–169.

- Küçükosmanoğlu, İ., Karanis, M. İ. E., Ünlü, Y., & Çöven, İ. (2022). Evaluation of P57, P53 and Ki67 Expression in Meningiomas. *Journal of Korean Neurosurgical Society*, 65(4), 499–506. <https://doi.org/10.3340/jkns.2021.0197>
- Kuhn, E., Kurman, R. J., Vang, R., Sehdev, A. S., Han, G., Soslow, R., Wang, T. L., & Shih, I. M. (2012). TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. *Journal of Pathology*, 226(3), 421–426. <https://doi.org/10.1002/path.3023>
- Kurman, R. J., & Shih, I. M. (2010). The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory. *American Journal of Surgical Pathology*, 34(3), 433–443. <https://doi.org/10.1097/PAS.0b013e3181cf3d79>
- Mackenzie, R., Kommoss, S., Winterhoff, B. J., Kipp, B. R., Garcia, J. J., Voss, J., Halling, K., Karnezis, A., Senz, J., Yang, W., Prigge, E. S., Reuschenbach, M., Doeberitz, M. V. K., Gilks, B. C., Huntsman, D. G., Bakkum-Gamez, J., McAlpine, J. N., & Anglesio, M. S. (2015). Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. *BMC Cancer*, 15(1), 1–10. <https://doi.org/10.1186/s12885-015-1421-8>
- Matsumura, N., Huang, Z., Baba, T., Lee, P. S., Barnett, J. C., Mori, S., Chang, J. T., Kuo, W. L., Gusberg, A. H., Whitaker, R. S., Gray, J. W., Fujii, S., Berchuck, A., & Murphy, S. K. (2009). Yin Yang 1 modulates taxane response in epithelial ovarian cancer. *Molecular Cancer Research*, 7(2), 210–220. <https://doi.org/10.1158/1541-7786.MCR-08-0255>
- Medeiros, F., Muto, M. G., Lee, Y., Elvin, J. A., Callahan, M. J., Feltmate, C., Garber, J. E., Cramer, D. W., & Crum, C. P. (2006). The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. *American Journal of Surgical Pathology*, 30(2), 230–236. <https://doi.org/10.1097/01.pas.0000180854.28831.77>
- Meliala, I. T. S., Hosea, R., Kasim, V., & Wu, S. (2020). The biological implications of Yin Yang 1 in the hallmarks of cancer. *Theranostics*, 10(9), 4183–4200. <https://doi.org/10.7150/thno.43481>
- Moioli, M., Barra, F., Maramai, M., Valenzano Menada, M., Vellone, V. G., Costantini, S., & Ferrero, S. (2019). Mucinous ovarian cancer: current therapeutic targets, preclinical progress, and experimental drugs. *Expert Opinion on Investigational Drugs*, 28(12), 1025–1029. <https://doi.org/10.1080/13543784.2019.1693999>
- Morice, P., Gouy, S., & Leary, A. (2019). Mucinous Ovarian Carcinoma. *New England Journal of Medicine*, 380(13), 1256–1266. <https://doi.org/10.1056/nejmra1813254>
- Piek, J. M. J., Van Diest, P. J., Zweemer, R. P., Jansen, J. W., Poort-Keesom, R. J. J., Menko, F. H., Gille, J. J. P., Jongsma, A. P. M., Pals, G., Kenemans, P., & Verheijen, R. H. M. (2001). Dysplastic changes in prophylactically removed

- Fallopian tubes of women predisposed to developing ovarian cancer. *Journal of Pathology*, 195(4), 451–456. <https://doi.org/10.1002/path.1000>
- Przybycin, C. G., Kurman, R. J., Ronnett, B. M., Shih, I. M., & Vang, R. (2010). Are all pelvic (Nonuterine) serous carcinomas of tubal origin? *American Journal of Surgical Pathology*, 34(10), 1407–1416. <https://doi.org/10.1097/PAS.0b013e3181ef7b16>
- Qian, S., Wang, W., & Li, M. (2020). Transcriptional factor Yin Yang 1 facilitates the stemness of ovarian cancer via suppressing miR-99a activity through enhancing its deacetylation level. *Biomedicine and Pharmacotherapy*, 126(March), 110085. <https://doi.org/10.1016/j.biopha.2020.110085>
- Rampersad, A. C., Wang, Y., Smith, E. R., & Xu, X. (2015). Menopause and ovarian cancer risk: mechanisms and experimental support. *Am J Clin Exp Obstet Gynecol*, 2(1), 14–23.
- Reid, B. M., Permuth, J. B., & Sellers, T. A. (2017). Epidemiology of ovarian cancer: a review. *Cancer Biology and Medicine*, 14(1), 9–32. <https://doi.org/10.20892/j.issn.2095-3941.2016.0084>
- Rojas, V., Hirshfield, K. M., Ganesan, S., & Rodriguez-Rodriguez, L. (2016). Molecular characterization of epithelial ovarian cancer: Implications for diagnosis and treatment. *International Journal of Molecular Sciences*, 17(12). <https://doi.org/10.3390/ijms17122113>
- Ryland, G. L., Hunter, S. M., Doyle, M. A., Caramia, F., Li, J., Rowley, S. M., Christie, M., Allan, P. E., Stephens, A. N., Bowtell, D. D. L., Campbell, I. G., & Gorringer, K. L. (2015). Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors. *Genome Medicine*, 7(1), 1–12. <https://doi.org/10.1186/s13073-015-0210-y>
- Sánchez-Prieto, M., Sánchez-Borrego, R., Lubián-López, D. M., & Pérez-López, F. R. (2022). Etiopathogenesis of ovarian cancer. An inflamm-aging entity? *Gynecologic Oncology Reports*, 42(May). <https://doi.org/10.1016/j.gore.2022.101018>
- Sarvagalla, S., Kolapalli, S. P., & Vallabhapurapu, S. (2019). The Two Sides of YY1 in Cancer: A Friend and a Foe. *Frontiers in Oncology*, 9(November), 10–13. <https://doi.org/10.3389/fonc.2019.01230>
- Shih, I. M., & Kurman, R. J. (2004). Ovarian Tumorigenesis: A Proposed Model Based on Morphological and Molecular Genetic Analysis. *American Journal of Pathology*, 164(5), 1511–1518. [https://doi.org/10.1016/S0002-9440\(10\)63708-X](https://doi.org/10.1016/S0002-9440(10)63708-X)
- Smith, E. R., & Xu, X. X. (2008). Ovarian ageing, follicle depletion, and cancer: a hypothesis for the aetiology of epithelial ovarian cancer involving follicle depletion. *The Lancet Oncology*, 9(11), 1108–1111. [https://doi.org/10.1016/S1470-2045\(08\)70281-X](https://doi.org/10.1016/S1470-2045(08)70281-X)
- Sung, P. L., Chang, Y. H., Chao, K. C., & Chuang, C. M. (2014). Global distribution pattern of histological subtypes of epithelial ovarian cancer: A database analysis

and systematic review. *Gynecologic Oncology*, 133(2), 147–154. <https://doi.org/10.1016/j.ygyno.2014.02.016>

Tarhriz, V., Bandehpour, M., Dastmalchi, S., Ouladsahebmadarek, E., Zarredar, H., & Eyvazi, S. (2019). Overview of CD24 as a new molecular marker in ovarian cancer. *Journal of Cellular Physiology*, 234(3), 2134–2142. <https://doi.org/10.1002/jcp.27581>

Wai, D. C. C., Shihab, M., Low, J. K. K., & Mackay, J. P. (2016). The zinc fingers of YY1 bind single-stranded RNA with low sequence specificity. *Nucleic Acids Research*, 44(19), 9153–9165. <https://doi.org/10.1093/nar/gkw590>

Wu, N. Y. Y., Fang, C., Huang, H. S., Wang, J., & Chu, T. Y. (2020). Natural history of ovarian high-grade serous carcinoma from time effects of ovulation inhibition and progesterone clearance of p53-defective lesions. *Modern Pathology*, 33(1), 29–37. <https://doi.org/10.1038/1379-019-0370-1>

Zhu, L. B. and W.-G. (2006). p53: Structure, Function and Therapeutic Applications. *Zhenkong Kexue Yu Jishu Xuebao/Journal of Vacuum Science and Technology*, 37(9), 862–865. <https://doi.org/10.13922/j.cnki.cjovst.2017.09.04>

